Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

uent to the acquisition. Acquired in-process research and development, a charge related to the purchase accounting of the OBS acquisition, totaled $3.8 billion for 2007. Equity income in 2007 totaled $2.0 billion, an increase of 40 percent compared to 2006.

Recent Developments

The company also offered the following summary of recent significant developments that have previously been announced, including:

-- Reported on results from two Phase II studies in patients with vascular

disease showing that TRA, a novel oral thrombin receptor antagonist,

does not increase the rate of major or minor bleeding in patients with

acute coronary syndrome or prior ischemic stroke when added to standard

antiplatelet therapy. (Announced Oct. 22, 2007)

-- Reported long-term follow-up results with the European Organization for

the Research and Treatment of Cancer Phase III trial that showed the

combination of TEMODAR (temozolomide) Capsules and radiation therapy

significantly prolonged survival in patients with glioblastoma

multiforme. (Announced Oct. 30, 2007)

-- Reported that the U.S. District Court for the District of Massachusetts

found no liability for Warrick Pharmaceuticals, the company's generic

subsidiary, in a class action lawsuit regarding average wholesale

prices for prescription products. (Announced Nov. 5, 2007)

-- Gained European Commission approval of PEGINTRON (peginterferon alfa-

2b) and REBETOL (ribavirin) combination therapy for retreating adult

patients with chronic hepatitis C whose prior treatment did not result

in a sustained response. (Announced Nov. 15, 2007)

-- Completed the acquisition of Organon BioSciences N.V. (Announced Nov.

19, 2007)

-- Merck/Schering-Plough Pharmaceuticals announced that an independent

panel of clinical and biostatistics experts had b
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Perrigo Company plc (NYSE: PRGO ... a portfolio of preclinical research assets, which it ... Corporation plc, to drug discovery and development company, ... will receive an upfront payment in addition to ... future sales derived from the portfolio. ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today ... highly effective new tool for organic growers. SUPPRESS™ ... contact herbicide for post-emergent, non-selective weed control for ... The formulation is an emulsifiable concentrate that has ... (OMRI) for use in organic food production. , ...
(Date:9/27/2014)... German . ... precisely surveying the surface topology of samples, but also ... exciting the atoms to fluoresce under irradiation by an ... provides information about the location and type of element, ... lighter elements of the periodic table such as lithium, ...
(Date:9/26/2014)... -- Research and Markets  has announced the addition ... Market Developments, Growth Areas and Opportunities" report to ... global end-user study and market analysis relating to the ... the laboratory. Market findings from this study ... research scientists and clinicians who routinely use nucleic acid ...
Breaking Biology Technology:Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2'Multi-spectra glasses' for scanning electron microscopy 2DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 2DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 3
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
(Date:9/29/2014)... beginning of the age of dinosaurs, gigantic reptilesdistant relatives ... and others in water and it was thought they ... University of Tennessee, Knoxville, researcher in the thigh of ... , Stephanie Drumheller, an earth and planetary sciences ... Sterling Nesbitt examined 220-million-year-old bite marks in the thigh ...
(Date:9/29/2014)... Institute (DOE JGI), a DOE Office of Science ... have been selected for the 2015 Community Science ... waters, and from plant root micro-ecosystems, to the ... the CSP 2015 projects portfolio highlights diverse environments ... , "These projects catalyze JGI,s strategic shift in ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4Tooth serves as evidence of 220 million-year-old attack 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... neighbors, and now researchers reporting in the June 22 issue ... they have a motive. It appears that chimps, and especially ... gain territory. "The take-home is clear and simple," ... each other. They kill their neighbors. Up until now, we ...
... which aims to develop a new, higher-yielding rice plant which could ... by an academic at the University of Sheffield. Currently, more ... a day and nearly one billion live in hunger. Over the ... about 50 per cent and water scarcity will grow. About half ...
... international public-private consortium to build the most detailed map ... of three pilot projects and the deposition of the ... use by the research community. In addition, work has ... database containing information from the genomes of 2,500 people ...
Cached Biology News:Why chimpanzees attack and kill each other 2Rice yields researched to tackle food security issues 2Rice yields researched to tackle food security issues 3Freely available data supporting next generation of human genetic research 2Freely available data supporting next generation of human genetic research 3Freely available data supporting next generation of human genetic research 4Freely available data supporting next generation of human genetic research 5Freely available data supporting next generation of human genetic research 6
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Biology Products: